Parallax Volatility Advisers
CNST

Parallax Volatility Advisers’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Parallax Volatility Advisers’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,000
Closed -$702K – 3799
2021
Q1 		$702K Buy
+30,000
New +$909K ﹤0.01% 2244

Other funds holding CNST

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Parallax Volatility Advisers's CNST Position: Q2 2021 in Review

Parallax Volatility Advisers sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 5,255 shares — an estimated $123K sold.

Parallax Volatility Advisers first reported a position in CNST in Q1 2021 and held it in 1 quarter. The position peaked at $123K in Q1 2021. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

  • Parallax Volatility Advisers reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Parallax Volatility Advisers sold 5,255 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $123K.
  • Parallax Volatility Advisers first reported a position in Constellation Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Parallax Volatility Advisers's Constellation Pharmaceuticals, Inc. position peaked at $123K in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Parallax Volatility Advisers's 13F filing for Q2 2021, filed 16 Aug 2021.